ALDX Aldeyra Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ALDX [NASD]

Aldeyra Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.75	Insider Own	4.90%	Shs Outstand	30.12M	Perf Week	10.89%
Market Cap	201.42M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	234.06%	Shs Float	22.60M	Perf Month	37.12%
Income	-49.30M	PEG	-	EPS next Q	-0.34	Inst Own	62.80%	Short Float	2.54%	Perf Quarter	150.18%
Sales	-	P/S	-	EPS this Y	-25.10%	Inst Trans	-0.03%	Short Ratio	0.39	Perf Half Y	33.77%
Book/sh	1.75	P/B	4.07	EPS next Y	-4.30%	ROA	-68.50%	Target Price	-	Perf Year	32.04%
Cash/sh	2.34	P/C	3.04	EPS next 5Y	-	ROE	-100.90%	52W Range	1.48 - 8.05	Perf YTD	22.72%
Dividend	-	P/FCF	-	EPS past 5Y	2.20%	ROI	-	52W High	-11.43%	Beta	2.25
Dividend %	-	Quick Ratio	14.50	Sales past 5Y	-	Gross Margin	-	52W Low	381.76%	ATR	0.65
Employees	20	Current Ratio	14.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	60.42	Volatility	9.44% 11.42%
Optionable	Yes	Debt/Eq	0.28	EPS Q/Q	49.40%	Profit Margin	-	Rel Volume	0.39	Prev Close	6.76
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Aug 06 BMO	Payout	-	Avg Volume	1.46M	Price	7.13
Recom	1.50	SMA20	12.27%	SMA50	35.28%	SMA200	50.13%	Volume	565,715	Change	5.47%

May-12-20

Initiated

Oppenheimer

Outperform

$12

Dec-04-18

Initiated

Citigroup

Buy

$23

Sep-26-18

Reiterated

Cantor Fitzgerald

Overweight

$23 → $30

Sep-13-18

Initiated

Janney

Buy

Jan-26-18

Initiated

Seaport Global Securities

Buy

$13

Sep-26-16

Initiated

H.C. Wainwright

Buy

$18

Jul-01-16

Initiated

Stifel

Buy

$16

Jul-01-15

Initiated

Canaccord Genuity

Buy

$16

Mar-25-15

Initiated

Chardan Capital Markets

Buy

$16

Mar-20-15

Reiterated

H.C. Wainwright

Buy

$13 → $14

Nov-18-14

Initiated

H.C. Wainwright

Buy

$13

Jun-19-14

Initiated

Aegis Capital

Buy

$35

Aug-06-20 10:09AM	Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus Zacks -9.38%
07:00AM	Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Aug-04-20 10:07AM	Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing? Zacks
08:00AM	Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire
Jul-30-20 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update Business Wire +8.53%
Jul-14-20 08:00AM	Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners Business Wire +21.28%
04:32AM	Aldeyra Spikes 10% In Pre-Market On New Perceptive Stake SmarterAnalyst
Jul-13-20 04:05PM	Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020 Business Wire
Jul-07-20 09:28PM	Aldeyra Therapeutics Inc (ALDX): Hedge Funds In Wait-and-See Mode Insider Monkey +8.25%
08:00AM	Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease Business Wire
Jul-03-20 11:15AM	What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)? Simply Wall St.
Jun-22-20 12:00PM	What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock Zacks -6.86%
Jun-18-20 10:12AM	Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study Zacks
Jun-15-20 08:00AM	Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program Business Wire
Jun-10-20 08:37PM	FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher Zacks
Jun-07-20 06:28PM	Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-04-20 08:00AM	Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease Business Wire
Jun-03-20 09:04AM	Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session Zacks -6.83%
08:00AM	Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-27-20 09:49AM	3 Strong Buy Biotech Stocks Under $5 With Explosive Upside Potential TipRanks
May-20-20 05:24PM	Covid Report: This Biotech Says Its Coronavirus Drug Topped Remdesivir Investor's Business Daily +13.80%
08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
07:00AM	Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting Business Wire
01:48AM	Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update Today SmarterAnalyst
May-19-20 04:05PM	Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update Business Wire -8.57%
May-15-20 08:53AM	How Aldeyra (ALDX) Stock Stands Out in a Strong Industry Zacks +20.00%
May-14-20 10:14AM	Top Ranked Momentum Stocks to Buy for May 14th Zacks +5.63%
May-13-20 12:00PM	Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should Know Zacks +5.97%
08:17AM	Aldeyra's Shares March Higher, Can It Continue? Zacks
May-07-20 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs Business Wire
Apr-16-20 06:35AM	These Mass. companies are developing COVID-19 treatments and tests American City Business Journals
Apr-15-20 09:47AM	Company News for Apr 15, 2020 Zacks
Apr-14-20 08:00AM	Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 Business Wire +27.82%
Apr-01-20 01:42AM	Edited Transcript of ALDX earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents -14.17%
Mar-24-20 12:00PM	What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock Zacks +22.87%
08:00AM	Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection Business Wire
Mar-18-20 06:13AM	Chair of the Board Richard Douglas Just Bought Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Simply Wall St. -15.35%
Mar-12-20 07:00AM	Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones Business Wire -13.26%
06:59AM	Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease Business Wire
Mar-05-20 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update Business Wire -5.31%
Mar-03-20 08:00AM	Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference Business Wire
Feb-24-20 08:00AM	Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day Business Wire
Feb-11-20 08:00AM	Aldeyra Therapeutics to Host 2020 Research & Development Day Business Wire
Jan-28-20 08:00AM	Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board Business Wire
Jan-21-20 08:00AM	Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis Business Wire
Jan-14-20 08:00AM	Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors Business Wire
Dec-21-19 07:07AM	The CEO, President & Director of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Todd Brady, Just Bought 8.7% More Shares Simply Wall St.
Dec-19-19 08:00AM	Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy Business Wire
Dec-13-19 03:07PM	Hedge Funds Are Selling Aldeyra Therapeutics Inc (ALDX) Insider Monkey
Dec-10-19 05:42PM	Edited Transcript of ALDX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +5.81%
Dec-03-19 12:42PM	Investors question Lexington startup's dry eye treatment American City Business Journals -32.44%
07:59AM	The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
07:13AM	Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment MarketWatch
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Business Wire
Dec-02-19 04:01PM	Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Business Wire -6.14%
Nov-12-19 08:00AM	Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-07-19 07:00AM	Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones Business Wire
Nov-01-19 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update Business Wire +5.01%
Oct-31-19 07:00AM	Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis Business Wire
Oct-30-19 04:01PM	Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis Business Wire
Oct-21-19 08:02AM	Does The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Share Price Fall With The Market? Simply Wall St.
Oct-13-19 04:33PM	The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-07-19 08:00AM	Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting Business Wire
Sep-26-19 08:00AM	Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting Business Wire
Sep-25-19 09:50AM	7 Stocks the Insiders Are Buying on Sale InvestorPlace
08:00AM	Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference Business Wire
Sep-24-19 08:00AM	Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy Business Wire
Sep-12-19 02:15AM	Aldeyra Therapeutics Inc (ALDX) President and CEO Todd C Brady Bought $102,800 of Shares GuruFocus.com
Sep-06-19 11:18AM	What Kind Of Shareholder Appears On The Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Shareholder Register? Simply Wall St.
Aug-30-19 11:24PM	Edited Transcript of ALDX earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-28-19 08:30AM	Aldeyra Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Aug-09-19 06:56PM	Aldeyra Therapeutics Inc (ALDX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:00AM	Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Jul-05-19 12:29PM	Heres What Hedge Funds Think About Aldeyra Therapeutics Inc (ALDX) Insider Monkey
Jun-25-19 09:26AM	No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails Benzinga -12.35%
07:39AM	Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals MarketWatch
07:00AM	Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis Business Wire
Jun-24-19 04:30PM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis Business Wire
May-30-19 08:00AM	Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 07:21PM	Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-09-19 03:23PM	Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript Motley Fool
07:00AM	Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 08:00AM	Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019 PR Newswire
Apr-30-19 08:00AM	Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial PR Newswire
Apr-09-19 08:00AM	Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting PR Newswire
Apr-02-19 08:00AM	Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease PR Newswire
Mar-27-19 05:09PM	Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge Zacks
10:00AM	Future Brightens for 2 Small Biotech Stocks TheStreet.com
Mar-26-19 01:14PM	Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today Motley Fool +35.99%
11:57AM	Aldeyra stock jumps 50 percent after eye allergy trial success American City Business Journals
10:37AM	Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
09:41AM	Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit? Simply Wall St.
07:51AM	Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints MarketWatch
07:46AM	Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis PR Newswire
Mar-25-19 04:01PM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis PR Newswire
Mar-13-19 10:35AM	Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock Zacks +5.50%
02:02AM	Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-08-19 12:12PM	Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM	Aldeyra Therapeutics Announces Year-End 2018 Financial Results PR Newswire

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Jul 09	Buy	4.25	3,200,000	13,600,000	6,285,458	Jul 13 04:30 PM
DOUGLAS RICHARD	Director	Mar 16	Buy	2.75	40,000	110,000	125,000	Mar 17 04:38 PM
Brady Todd C	President and CEO	Dec 16	Buy	5.10	20,000	101,908	652,216	Dec 18 07:35 AM
Brady Todd C	President and CEO	Sep 30	Buy	5.68	8,710	49,483	632,216	Oct 02 07:36 AM
Brady Todd C	President and CEO	Sep 23	Buy	5.81	8,680	50,433	623,506	Sep 25 07:40 AM
Brady Todd C	President and CEO	Sep 18	Buy	5.91	14,288	84,465	614,826	Sep 20 07:37 AM
Bronstein Ben	Director	Sep 17	Buy	5.85	1,700	9,945	18,644	Sep 19 04:23 PM
Brady Todd C	President and CEO	Sep 16	Buy	6.03	3,000	18,090	591,991	Sep 17 07:35 AM
DOUGLAS RICHARD	Director	Sep 13	Buy	6.00	5,000	30,000	85,000	Sep 17 07:36 AM
Brady Todd C	President and CEO	Sep 13	Buy	5.79	10,000	57,900	588,991	Sep 17 07:35 AM
JOYCE MARTIN JOSEPH	Director	Sep 12	Buy	5.86	1,700	9,964	19,644	Sep 16 04:15 PM
DOUGLAS RICHARD	Director	Sep 12	Buy	6.03	10,000	60,276	80,000	Sep 13 07:54 AM
DOUGLAS RICHARD	Director	Sep 11	Buy	5.75	10,000	57,529	70,000	Sep 13 07:54 AM
Brady Todd C	President and CEO	Sep 10	Buy	5.39	10,000	53,937	578,991	Sep 11 04:05 PM
DOUGLAS RICHARD	Director	Sep 10	Buy	5.09	10,000	50,857	60,000	Sep 11 04:05 PM
DOUGLAS RICHARD	Director	Sep 09	Buy	4.91	10,000	49,106	50,000	Sep 11 04:05 PM
Brady Todd C	President and CEO	Sep 09	Buy	4.89	10,000	48,887	568,991	Sep 11 04:05 PM
Clark David J	Chief Medical Officer	Sep 06	Buy	5.06	5,000	25,311	17,878	Sep 10 05:01 PM
Reed Joshua	Chief Financial Officer	Sep 05	Buy	4.71	3,200	15,072	35,774	Sep 09 04:38 PM
McMullin David	Chief Commerical Officer	Sep 05	Buy	4.68	4,329	20,260	6,148	Sep 09 04:37 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience